Clinical trials: Glabellar Lines, active
Glabellar Lines
To Evaluate HU-045 With Moderate to Severe Glabellar Lines
A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HU-045 and Xeomin® in Patients With Moderate to Severe Glabellar Lines
- Trial name
- NCT07870694
- Testing
- HU-045, Xeomin®
- Where
- South Korea
- Volunteers
- 390 people, healthy volunteers welcome
- Sponsor
- Huons Biopharma
Upper Facial Lines, Glabellar Lines
A Study to Assess the Safety and Efficacy of Co-Reconstituted TrenibotulinumtoxinE and OnabotulinumtoxinA in Adult Participants With Moderate to Severe Upper Facial Lines
The objective of this Phase 2 study is to assess the safety and efficacy of single treatment of trenibotulinumtoxinE and onabotulibumtoxinA combination in adult participants with moderate to severe upper facial lines.
- Trial name
- NCT07871513
- Testing
- TrenibotulinumtoxinE and OnabotulinumtoxinA, OnabotulinumtoxinA
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- AbbVie
Moderate to Severe Glabellar Lines
A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows
The purpose of this study is to assess the effectiveness and safety of a single dose of Corabotase (also known as IPN10200) compared to placebo (double-blind phase) and how well and safely repeat doses of Corabotase work over…
- Trial name
- LAURITE 2 (NCT07435428)
- Testing
- Corabotase
- Where
- 60 sites in United States, France and 2 more
- Volunteers
- 1,300 people
- Sponsor
- Ipsen
Moderate to Severe Glabellar Lines
Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection to Treat Moderate to Severe Glabellar Lines
This is a Phase 3 clinical study to evaluate the efficacy, safety, and immunogenicity of single/repeated injections of Eveotox in the treatment of moderate to severe glabellar lines.
- Trial name
- NCT06937944
- Testing
- Rcombinant botulinum toxin type A for injection（Eveotox), OnabotulinumtoxinA (Botox)
- Where
- 15 sites in China
- Volunteers
- 669 people
- Sponsor
- JHM BioPharma (Tonghua) Co. , Ltd.
Moderate to Severe Glabellar Lines
A Study to Assess the Effectiveness and Safety of IPN10200 in Adult Chinese Participants With Moderate to Severe Wrinkle-like Lines Between the Eyebrows
The purpose of this study is to find out about the effectiveness and safety of a single dose of corabotase (also known as IPN10200) compared to placebo works in participants with moderate to severe glabellar lines.
- Trial name
- LAURITE 3 (NCT07779252)
- Testing
- Corabotase
- Where
- 9 sites in China
- Volunteers
- 160 people
- Sponsor
- Ipsen
Moderate to Severe Glabellar Lines
A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows
The purpose of this study is to assess the effectiveness and safety of Corabotase (also known as IPN10200) compared to placebo in the improvement of the appearance of moderate to severe glabellar lines in adult participants.
- Trial name
- LAURITE 1 (NCT07427797)
- Testing
- Corabotase
- Where
- 23 sites in United States, Canada
- Volunteers
- 309 people
- Sponsor
- Ipsen
Glabellar Lines
A Study to Evaluate Sequential Administration of Injections of AGN-151586 Followed by BOTOX in Adult Participants for Treatment of Glabellar Lines
Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin.
- Trial name
- NCT07756580
- Testing
- AGN-151586, BOTOX
- Where
- 8 sites in United States
- Volunteers
- 120 people
- Sponsor
- AbbVie
Glabellar Lines
Study of DWP450 in Japanese Subjects With Glabellar Lines
Study to Evaluate the Efficacy and Safety of DWP450 in Japanese Subjects with Moderate to Severe Glabellar Lines
- Trial name
- NCT07783763
- Testing
- DWP450 20 U, 0.9% Saline Solution 0.5 mL
- Volunteers
- 120 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Wrinkle, Glabellar Frown Lines
Head-to-Head Comparison of All Botulinum Neurotoxin Type A Products for Glabellar Rhytides
Study Type: This is a multicenter, triple-blind, randomized controlled trial. Purpose: The goal of this clinical trial is to compare the effectiveness and safety of all commercially available Botulinum Neurotoxin Type A (BoNT-A)…
- Conditions
- Wrinkle, Glabellar Frown Lines, Glabellar Furrowing
- Trial name
- NCT06448676
- Testing
- Botulinum toxin type A
- Where
- 3 sites in Netherlands
- Volunteers
- 325 people, healthy volunteers welcome
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Glabellar Frown Lines
Depth of Botulinum Neurotoxin Injection for Treatment of Glabellar Lines
STUDY QUESTION: Does the depth of injection of onabotulinumtoxinA neurotoxin in the glabellar complex affect efficacy of the BoTN for the improvement of glabellar frown lines? STUDY AIM Primary objective: Compare the efficacy of…
- Trial name
- NCT05766683
- Testing
- onabotulinumtoxinA at a depth of 2mm, onabotulinumtoxinA at a depth of 4mm
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Henry Ford Health System
Glabellar Lines
A Study to Evaluate AI-09 In Participants With Glabellar Lines
Phase 2 clinical study to evaluate the efficacy, safety, and tolerability of AI-09, a Ready-to-Use Liquid Injectable Botulinum Toxin.
- Trial name
- NCT07321834
- Testing
- AI-09 Ready Use Injectable Botulinum Toxin, Vehicle
- Where
- 5 sites in United States
- Volunteers
- 68 people
- Sponsor
- Eirion Therapeutics Inc.
Glabellar Lines
Evaluate the Efficacy and Safety of DWP712 With Moderate to Severe Glabellar Lines
To evaluate the efficacy and safety of DWP712 Inj. in Subjects with Moderate to Severe Glabellar Lines
- Trial name
- NCT07013279
- Testing
- DWP712 inj., Botox® 100 Units
- Where
- South Korea
- Volunteers
- 324 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Glabellar Lines
To Evaluate HU-045 in the Treatment of Glabellar Lines(Phase III)
A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HU-045 and Xeomin® in Patients With Moderate to Severe Glabellar Lines
- Trial name
- NCT06205797
- Testing
- HU-045, Xeomin®
- Where
- South Korea
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- Huons Biopharma